Ascendis Pharma A/S, a biopharmaceutical firm, is dedicated to addressing the medical community's unmet needs. Its leading treatment SKYTROFA is geared towards patients suffering from growth hormone deficiency (GHD). Ascendis Pharma is also advancing TransCon Growth Hormone to target pediatric GHD, adult GHD, and Turner syndrome; TransCon Parathyroid Hormone for treating hypoparathyroidism in adults; and TransCon C-type natriuretic peptide to combat achondroplasia. The organisation is making strides in the development of TransCon toll like receptors 7/8 agonist for intratumoral delivery and TransCon IL-2 ß/? for systemic delivery. Founded in 2006, the Denmark-based biopharmaceutical company has its headquarters in Hellerup.
Ascendis Pharma's ticker is ASND
The company's shares trade on the TSX stock exchange
They are based in Toronto, Ontario
There are 11-50 employees working at Ascendis Pharma
It is ascendispharma.com
Ascendis Pharma is in the Basic Materials sector
Ascendis Pharma is in the Industrial Metals & Minerals industry
The following five companies are Ascendis Pharma's industry peers: